Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 5.

Journal Article

Altomare, D., Festari, C., Rivolta, J., Gandolfo, F., Orini, S., Drzezga, A., Nobili, F. and Boccardi, M. (2017). Diagnostic utility of FDG-PET in identifying AD dementia with atypical presentation or atypical course. Eur. J. Neurol., 24. S. 610 - 611. HOBOKEN: WILEY. ISSN 1468-1331

Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V. and Hansson, O. (2021). The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur. J. Nucl. Med. Mol. Imaging, 48 (7). S. 2140 - 2157. NEW YORK: SPRINGER. ISSN 1619-7089

Leuzy, A., Ashton, N. J., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V. and Hansson, O. (2021). 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur. J. Nucl. Med. Mol. Imaging, 48 (7). S. 2121 - 2140. NEW YORK: SPRINGER. ISSN 1619-7089

Nobili, F., Arbizu, J., Bouwman, F., Drzezga, A., Agosta, F., Nestor, P., Walker, Z. and Boccardi, M. (2018). European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain F-18-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur. J. Neurol., 25 (10). S. 1201 - 1218. HOBOKEN: WILEY. ISSN 1468-1331

Wolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Hansson, O., Nordberg, A., Frisoni, G. B., Garibotto, V and Ossenkoppele, R. (2021). Clinical validity of increased cortical uptake of [F-18]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. Eur. J. Nucl. Med. Mol. Imaging, 48 (7). S. 2097 - 2110. NEW YORK: SPRINGER. ISSN 1619-7089

This list was generated on Fri Apr 26 20:42:44 2024 CEST.